Brief Title
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Official Title
A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy
Brief Summary
This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
Biochemical control (% of patients) as measured by GH- and IGF-1-values (baseline, EOS)
Secondary Outcome
Effect of tumor size
Condition
Acromegaly
Intervention
Octreotide acetate and cabergoline/Octrotide and Somavert
Study Arms / Comparison Groups
SMS995 + Carbegolin, Somavert + SMS995
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
20
Start Date
March 2006
Primary Completion Date
January 2010
Eligibility Criteria
Inclusion criteria: - Male and female patients (> 18 years) with prior surgery of micro- or macroadenoma of the pituitary. - At least 6 months chronic treatment with 30mg octreotide (long acting release). - Partial responsiveness, which is defined as follows: at any one point within the 6 months monotherapy with 30mg/month octreotide (long acting release) the patient must have experienced a decrease in GH and IGF-1 of at least 25% as compared to pre-monotherapy values (= baseline). Note: For efficacy analysis GH- and IGF-1-values measured in the central laboratory at visit 1 (=study baseline) will be used. - Lack of suppression of GH nadir to < 1.0 µg/L, after oral administration of 75 g of glucose (OGTT) and IGF-I levels at least 10% above the normal value ± 2 SD (adjusted for age and gender; Brabant 2003) must be proven within 4 weeks prior to visit 1. However, if acromegaly symptoms are inadequately controlled as defined in the acromegaly comorbidities and symptom evaluation (as judged by the investigator), an abnormal GH or IGF-1-value as defined above is sufficient. - Patient's written informed consent. Exclusion criteria: - Requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass. - Radiotherapy planned or radiotherapy for acromegaly within the last 2 years. - Symptomatic cholelithiasis that is clinically relevant. - Receiving treatment with dopamine agonists within the last 6 months or prior treatment with GH-receptor-antagonists. - Patients with renal insufficiency, Raynaud-Syndrome or gastrointestinal ulcer/ bleeding cannot be included in the study or psychose in anamnesis. Other protocol-defined inclusion/exclusion criteria may apply
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Novartis Pharmaceuticals, ,
Location Countries
Germany
Location Countries
Germany
Administrative Informations
NCT ID
NCT00376064
Organization ID
CSMS995BDE16
Responsible Party
Sponsor
Study Sponsor
Novartis Pharmaceuticals
Study Sponsor
Novartis Pharmaceuticals, Study Director, Novartis Pharmeceuticals
Verification Date
September 2011